Evidence map›Paper›PMID 41235374›Full record

ArticleClinical case reports2025

Successful Treatment of Post-SARS-CoV-2 Infection Reactive Arthritis With Secukinumab: A Case Report and Literature Review.

Qi Zhao, Tianyu Yao, Danyue He, Jie Hu, Yulin Wang, Ruyi Wang, Yiyang Hu, Chengyu Li, Jia Cai, Xiangning Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qi ZhaoDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.
Tianyu YaoDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.
Danyue HeDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.
Jie HuDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.
Yulin WangDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.ORCID https://orcid.org/0009-0007-7136-8581
Ruyi WangDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.
Yiyang HuDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.
Chengyu LiThe First Clinical Medical College Anhui Medical University Hefei Anhui China.
Jia CaiThe First Clinical Medical College Anhui Medical University Hefei Anhui China.
Xiangning LiThe First Clinical Medical College Anhui Medical University Hefei Anhui China.
Lili TangDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.
Xing FanDepartment of Dermatology, The First Affiliated Hospital Anhui Medical University Hefei Anhui China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case describes a rare occurrence of post-SARS-CoV-2 infection reactive arthritis with psoriasiform lesions. The patient failed to respond to conventional therapies but responded well to secukinumab, underscoring that it may be a valuable treatment for refractory post-SARS-CoV-2 infection reactive arthritis when conventional therapies fail.

Indexed as

biologic therapyIL‐17A inhibitorreactive arthritisSARS‐CoV‐2Secukinumab

Identifiers

PMID41235374
PMCPMC12605951

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.